XBITHealthcare · BiotechnologyXBIT Stock Forecast: XBiotech, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 22 Aug 2026 — in the lower half.
XBIT stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores XBiotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (79): Smaller than most of the companies we track.
Value (10): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
XBIT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on XBIT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Apr 2020 | Piper Sandler | Maintains | Overweight | $28 → $18 |
| 7 Apr 2020 | Piper Sandler | Maintains | Overweight | — |
| 11 Dec 2019 | Piper Sandler | Maintains | Overweight | — |
| 11 Dec 2019 | PiperJaffray | Maintains | Overweight | — |
| 14 June 2019 | Piper Jaffray | Initiates | Overweight | — |
| 14 June 2019 | Piper Sandler | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XBIT appears on the weeks it earns a place.
XBIT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
XBiotech, Inc. (XBIT) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −1.5×
- Price / sales
- —
- Price / book
- 0.5×
- EV / EBITDA
- 0.9×
Cheaper than 84% of US stocks
Cheaper than 84% of US stocks
Cheaper than 58% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −29.9%
- Return on assets
- −19.3%
- Dividend yield
- —
Higher than 27% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
XBIT vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own XBiotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about XBIT stock
How does Ticker Nerd's model rank XBIT?
As at 22 Aug 2026, XBiotech, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (79 of 100).
What is the XBIT stock forecast for 2030?
No analyst covering XBiotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XBIT are extrapolating price history, which says nothing about the business.
How has XBIT stock performed over the past year?
XBiotech, Inc. returned -28.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does XBiotech, Inc. do?
XBiotech Inc. is a biotechnology company involved in the development, production, and commercialization of therapeutic antibodies designed to treat serious human diseases.
About XBiotech, Inc.
XBiotech Inc. is a biotechnology company involved in the development, production, and commercialization of therapeutic antibodies designed to treat serious human diseases. This company focuses on its proprietary True Human™ antibodies, which are derived from natural human immunity rather than genetically engineered models. The primary purpose of these therapies is to target chronic inflammatory conditions, infectious diseases, and cancer while minimizing potential side effects associated with synthetic antibodies. Founded in 2005 and headquartered in Austin, Texas, XBiotech's research and innovation seek to impact sectors such as healthcare and pharmaceuticals significantly. The company's efforts are centered on advancing medicine by using the human body's natural immune responses to deliver safer and more effective treatments. XBiotech's work represents a pivotal role in the biotechnology landscape as it pushes forward with groundbreaking research aimed at changing therapeutic approaches to human health. By leveraging innovative biotechnology, XBiotech Inc. continues to contribute to developments that could reshape patient care across various medical fields.
CEO Dr. Sushma Shivaswamy Ph.D. · 87 employees · United States · https://www.xbiotech.com